Who makes Tetracycline slurry?

Tetracycline slurry is developed by Aristotle University Of Thessaloniki.

What development phase is Tetracycline slurry in?

Tetracycline slurry is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Tetracycline slurry

Aristotle University Of Thessaloniki · FDA-approved active Small molecule Quality 0/100

Tetracycline slurry, marketed by Aristotle University of Thessaloniki, is an established antibiotic with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and long-term use. The primary risk is the potential increase in generic competition following the patent expiry in 2028.

At a glance

Generic name	Tetracycline slurry
Also known as	Labrida Bioclean
Sponsor	Aristotle University Of Thessaloniki
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Non-surgical Treatment of Peri-implantitis Using Chitosan Brush and Tetracycline Slurry (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tetracycline slurry CI brief — competitive landscape report
Tetracycline slurry updates RSS · CI watch RSS
Aristotle University Of Thessaloniki portfolio CI